| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/JNCI/DJS427 |
| P698 | PubMed publication ID | 23104212 |
| P50 | author | David Cunningham | Q38803238 |
| Roberto Labianca | Q39950156 | ||
| Roberto Fiocca | Q40709161 | ||
| Dirk Klingbiel | Q57611695 | ||
| P2093 | author name string | Eric Van Cutsem | |
| Mauro Delorenzi | |||
| Sabine Tejpar | |||
| Bernard Nordlinger | |||
| Arnaud D Roth | |||
| Pu Yan | |||
| Fred Bosman | |||
| Laura Cisar | |||
| Giovanni d'Ario | |||
| P2860 | cites work | Molecular origins of cancer: Molecular basis of colorectal cancer | Q24617331 |
| KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. | Q27851422 | ||
| A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis | Q28269226 | ||
| Molecular predictors of survival after adjuvant chemotherapy for colon cancer | Q28363159 | ||
| Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes | Q28508338 | ||
| Colorectal carcinogenesis: road maps to cancer | Q33291970 | ||
| Simpson's paradox visualized: the example of the rosiglitazone meta-analysis | Q33338989 | ||
| Revised TN categorization for colon cancer based on national survival outcomes data | Q33516922 | ||
| Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer | Q33586020 | ||
| Clinical trial designs for predictive biomarker validation: one size does not fit all. | Q34097089 | ||
| Prognostic and predictive factors in colorectal cancer | Q34597916 | ||
| Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. | Q35170271 | ||
| The role of SMAD4 in early-onset colorectal cancer | Q35587027 | ||
| Strategies for identifying hereditary nonpolyposis colon cancer | Q36963461 | ||
| Deficient mismatch repair system in patients with sporadic advanced colorectal cancer | Q37081098 | ||
| Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. | Q37157691 | ||
| Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers | Q37369820 | ||
| Genetic prognostic and predictive markers in colorectal cancer | Q37523207 | ||
| Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial | Q43290037 | ||
| DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study | Q44210955 | ||
| Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer | Q45837382 | ||
| Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. | Q46006799 | ||
| Microsatellite instability and colorectal cancer prognosis. | Q46831092 | ||
| Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. | Q51502354 | ||
| Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. | Q51597972 | ||
| Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis. | Q52551767 | ||
| Unbiased Recursive Partitioning: A Conditional Inference Framework | Q56340213 | ||
| SMAD4 as a Prognostic Marker in Colorectal Cancer | Q57567752 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colon cancer | Q18555025 |
| P304 | page(s) | 1635-1646 | |
| P577 | publication date | 2012-10-25 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer | |
| P478 | volume | 104 |
| Q35150637 | A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer |
| Q37413869 | A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers |
| Q52579497 | A four-microRNA classifier as a novel prognostic marker for tumor recurrence in stage II colon cancer. |
| Q39454414 | A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics. |
| Q36315165 | AJCC Cancer Staging Manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment? |
| Q92012575 | Adjuvant Therapy for High-Risk Stage II or III Colon Adenocarcinoma: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study |
| Q38222249 | Advances in the management of colorectal cancer: from biology to treatment |
| Q37409562 | Analysis of histological and immunological parameters of metastatic lymph nodes from colon cancer patients reveals that T-helper 1 type immune response is associated with improved overall survival |
| Q36299382 | Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer |
| Q49871641 | Association of rs2282679 A>C polymorphism in vitamin D binding protein gene with colorectal cancer risk and survival: effect modification by dietary vitamin D intake |
| Q33615076 | BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer. |
| Q54590412 | Biomarker for high-risk patients with stage II colon cancer. |
| Q37114675 | Biomarker in Colorectal Cancer. |
| Q91754859 | Biomarker-guided therapy for colorectal cancer: strength in complexity |
| Q37706705 | Building personalized treatment plans for early-stage colorectal cancer patients |
| Q37741987 | Clinical course and outcome of patients with high-level microsatellite instability cancers in a real-life setting: a retrospective analysis |
| Q50878258 | Clinical significance of VEGFR-2 and ¹⁸F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy. |
| Q36344547 | Colorectal Cancer: Personalized Therapy |
| Q38124901 | Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis |
| Q58695712 | Comparison of the eighth version of the American Joint Committee on Cancer manual to the seventh version for colorectal cancer: A retrospective review of our data |
| Q55260487 | Confirmation of a metastasis-specific microRNA signature in primary colon cancer. |
| Q35001203 | Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer |
| Q40411498 | Copy number variations in DCC/18q and ERBB2/17q are associated with disease-free survival in microsatellite stable colon cancer |
| Q38787244 | Current and future biomarkers in the treatment of colorectal cancer. |
| Q33829763 | Current status of gene expression profiling to assist decision making in stage II colon cancer |
| Q35048299 | Deciphering genomic alterations in colorectal cancer through transcriptional subtype-based network analysis |
| Q34656360 | Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. |
| Q35067307 | Evaluation of relapse-free survival in T3N0 colon cancer: the role of chemotherapy, a multicentric retrospective analysis |
| Q38683093 | Expending Role of Microsatellite Instability in Diagnosis and Treatment of Colorectal Cancers. |
| Q91804218 | External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP, BRAF and KRAS |
| Q58407923 | Frequent intragenic rearrangements of DPYD in colorectal tumours |
| Q54237552 | Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma. |
| Q37578728 | Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer |
| Q92830555 | Genomics-Enabled Precision Medicine for Cancer |
| Q42366278 | High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemonaive lymph node negative colon cancer patients. |
| Q41721184 | Human cytomegalovirus and Epstein-Barr virus infection impact on (18)F-FDG PET/CT SUVmax, CT volumetric and KRAS-based parameters of patients with locally advanced rectal cancer treated with neoadjuvant therapy |
| Q36289304 | IGFBP-3 Gene Methylation in Primary Tumor Predicts Recurrence of Stage II Colorectal Cancers |
| Q38873106 | Immunohistochemical expression pattern of MMR protein can specifically identify patients with colorectal cancer microsatellite instability |
| Q54193016 | Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas. |
| Q38703244 | Impact of MLH1 expression on tumor evolution after curative surgical tumor resection in a murine orthotopic xenograft model for human MSI colon cancer |
| Q26772272 | Implications of mismatch repair-deficient status on management of early stage colorectal cancer |
| Q38473480 | Integrating biomarkers in colorectal cancer trials in the West and China |
| Q93134021 | Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer |
| Q37594355 | Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway |
| Q38939839 | MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer |
| Q34344060 | Meta-analysis of the prognostic value of smad4 immunohistochemistry in various cancers |
| Q43345082 | Metabolic and molecular relative percentage coreduction in patients with locally advanced rectal cancer treated with neoadjuvant therapy |
| Q37564379 | MicroRNA-20a-5p promotes colorectal cancer invasion and metastasis by downregulating Smad4. |
| Q37075412 | Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication |
| Q35191237 | Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer |
| Q36124008 | Microsatellite instability testing and its role in the management of colorectal cancer. |
| Q33682949 | Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study |
| Q53299071 | Mononucleotide repeats in the SMAD4 gene promoter in colon carcinoma tissue of Croatian patients. |
| Q94526774 | Outcomes of Adjuvant Oral versus Intravenous Fluoropyrimidines for High-Risk Stage II or Stage III Colon Adenocarcinoma: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study |
| Q92143971 | Over expression of METRN predicts poor clinical prognosis in colorectal cancer |
| Q47793305 | Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I-II colon cancer patients |
| Q57207899 | Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial |
| Q38390834 | Personalized treatment for patients with colorectal cancer: role of biomarkers |
| Q38179024 | Precision treatment for cancer: role of prognostic and predictive markers |
| Q33608167 | Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study |
| Q38089481 | Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance |
| Q38421451 | Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. |
| Q36006605 | Prognostic Role of BRAF Mutation in Stage II/III Colorectal Cancer Receiving Curative Resection and Adjuvant Chemotherapy: A Meta-Analysis Based on Randomized Clinical Trials |
| Q33735239 | Prognostic and predictive significance of MSI in stages II/III colon cancer |
| Q34982575 | Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy |
| Q37111201 | Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location |
| Q37746284 | Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer |
| Q41822265 | Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial. |
| Q35625752 | Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage |
| Q58795161 | Real-World Implications of Nonbiological Factors with Staging, Prognosis and Clinical Management in Colon Cancer |
| Q88709390 | Real-world study of a novel prognostic scoring system: for a more precise prognostication and better clinical treatment guidance in stages II and III colon cancer |
| Q42223681 | Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer |
| Q94410957 | Response |
| Q28080176 | Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer |
| Q54219261 | Short leukocyte telomere length predicts poor prognosis and indicates altered immune functions in colorectal cancer patients. |
| Q35763172 | Single Nucleotide Polymorphism (rs4932178) in the P1 Promoter of FURIN Is Not Prognostic to Colon Cancer |
| Q46676671 | Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer |
| Q37310011 | Striking similarities in genetic aberrations between a rectal tumor and its lung recurrence |
| Q97649658 | Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer |
| Q61867795 | Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial |
| Q36038603 | TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients |
| Q30854540 | Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data |
| Q36090214 | The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis |
| Q39405225 | The future of colorectal cancer: implications of screening |
| Q55233897 | The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy. |
| Q38880745 | The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets |
| Q92714480 | The prognostic significance of FBXO2 expression in colorectal cancer |
| Q33679614 | The prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon cancer |
| Q35828678 | The prognostic value of the stem-like group in colorectal cancer using a panel of immunohistochemistry markers |
| Q34169734 | Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis |
| Q34441837 | Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update |
| Q39306576 | What We Know About Stage II and III Colon Cancer: It's Still Not Enough |
| Q36315152 | What is the optimal means of staging colon cancer? |
Search more.